Gastrointestinal motility reduced single-fraction target coverage and broadened organ-at-risk dose ranges, while conventional fractionation substantially attenuated the interplay effect.
Adding early stereotactic body radiotherapy to neoadjuvant chemoimmunotherapy was associated with median progression-free survival of 12.5 versus 6.6 months.
Oxygen-ion irradiation showed higher biological effectiveness and more persistent DNA damage than carbon ions or photons in pancreatic cancer cells.
Four-dimensional prompt-gamma imaging detected clinically relevant proton range shifts associated with anatomical change during pancreatic proton therapy.
Standardized two-hour fasting produced reproducible stomach volumes in only 42% of patients receiving magnetic resonance-guided pancreatic stereotactic radiotherapy.